| . | No cardiac NLE (N = 38) . | Cardiac NLE (N = 7) . | P values . |
|---|---|---|---|
| Maternal characteristics | |||
| Maternal diagnosis | 0.03 | ||
| Asymptomatic | 6 (16) | 4 (58) | |
| SLE | 24 (63) | 1 (14) | |
| SS | 4 (10) | 1 (14) | |
| SLE/SS | 1 (3) | 0 (0) | |
| UCTD | 2 (5) | 0 (0) | |
| APS | 0 (0) | 1 (14) | |
| Dysautonomia | 1 (3) | 0 (0) | |
| Positive anti-La antibody | 12 (32) | 4 (57) | 0.24 |
| Maternal intake of fluorinated steroids | 0 (0) | 7 (100) | <0.01 |
| Maternal intake of IVIG | 1 (3) | 4 (58) | <0.01 |
| Maternal intake of non-fluorinated steroids | 7 (18) | 0 (0) | 0.57 |
| Maternal intake of antimalarials | 14 (37) | 1 (14) | 0.40 |
| Prenatal complicationsa | 8 (21) | 3 (43) | 0.34 |
| Vaginal delivery | 24 (63) | 1 (14) | 0.03 |
| Infant characteristics | |||
| Sex F:M | 19:19 (50:50) | 5:2 (71:29) | 0.42 |
| Gestational age, weeks | 38.0 (37.0–39.0) | 35.5 (34.5–38.0) | 0.03 |
| Birth weight, kg | 3.0 (2.6–3.5) | 2.3 (1.8–2.5) | 0.02 |
| Neonatal complicationsb | 9 (24) | 2 (29) | 0.99 |
| Infant received non-fluorinated steroids | 0 (0) | 7 (100) | <0.01 |
| Infant received IVIG | 0 (0) | 5 (71) | <0.01 |
| Age at first hs-cTnT measurement, days | 55 (43–78) | 5 (2–26) | <0.01 |
| First hs-cTnT measurement, ng/l | 37 (24–61) | 67 (49–310)c | 0.03 |
| . | No cardiac NLE (N = 38) . | Cardiac NLE (N = 7) . | P values . |
|---|---|---|---|
| Maternal characteristics | |||
| Maternal diagnosis | 0.03 | ||
| Asymptomatic | 6 (16) | 4 (58) | |
| SLE | 24 (63) | 1 (14) | |
| SS | 4 (10) | 1 (14) | |
| SLE/SS | 1 (3) | 0 (0) | |
| UCTD | 2 (5) | 0 (0) | |
| APS | 0 (0) | 1 (14) | |
| Dysautonomia | 1 (3) | 0 (0) | |
| Positive anti-La antibody | 12 (32) | 4 (57) | 0.24 |
| Maternal intake of fluorinated steroids | 0 (0) | 7 (100) | <0.01 |
| Maternal intake of IVIG | 1 (3) | 4 (58) | <0.01 |
| Maternal intake of non-fluorinated steroids | 7 (18) | 0 (0) | 0.57 |
| Maternal intake of antimalarials | 14 (37) | 1 (14) | 0.40 |
| Prenatal complicationsa | 8 (21) | 3 (43) | 0.34 |
| Vaginal delivery | 24 (63) | 1 (14) | 0.03 |
| Infant characteristics | |||
| Sex F:M | 19:19 (50:50) | 5:2 (71:29) | 0.42 |
| Gestational age, weeks | 38.0 (37.0–39.0) | 35.5 (34.5–38.0) | 0.03 |
| Birth weight, kg | 3.0 (2.6–3.5) | 2.3 (1.8–2.5) | 0.02 |
| Neonatal complicationsb | 9 (24) | 2 (29) | 0.99 |
| Infant received non-fluorinated steroids | 0 (0) | 7 (100) | <0.01 |
| Infant received IVIG | 0 (0) | 5 (71) | <0.01 |
| Age at first hs-cTnT measurement, days | 55 (43–78) | 5 (2–26) | <0.01 |
| First hs-cTnT measurement, ng/l | 37 (24–61) | 67 (49–310)c | 0.03 |
Data shown as median (IQR) or N (%), unless otherwise specified.
Prenatal complications in mothers of infants without cardiac NLE: premature rupture of membranes (N = 1), deep venous thrombosis (N = 1), pemphigoïd gestationis (N = 1), hypertension (N = 2), oligohydramnios (N = 1), maternal fever during labour (N = 1) and fetal growth delay (N = 1); prenatal complications in mothers of infants with cardiac NLE: paronychia and upper respiratory tract infection (N = 1), oligohydramnios (N = 1) and gestational diabetes (N = 1).
Neonatal complications in infants without cardiac NLE: NLE-related thrombocytopenia (N = 1), hyperbilirubinemia requiring phototherapy (N = 2), umbilical cord knot (N = 1), nuchal cord, vacuum-assisted delivery and CPAP requirement for 24 h (N = 1), hypoglycaemia (N = 1), transient heart-rate irregularity (N = 1), gastrointestinal infection (N = 1) and group B Streptococcal sepsis and hyperbilirubinemia requiring phototherapy (N = 1); neonatal complications in infants with cardiac NLE: intubation and haemodynamic instability requiring vasopressors (N = 2).
Median (IQR) of first hs-cTnT measurement, ng/l in cardiac NLE infants (N = 5) without a pacemaker inserted: 65 (37–78); P = 0.20 vs infants without cardiac NLE. CPAP: continuous positive airway pressure; F: female; hs-cTnT: high-sensitivity cardiac troponin T; IQR: interquartile range; M: male; NLE: neonatal lupus erythematosus.
| . | No cardiac NLE (N = 38) . | Cardiac NLE (N = 7) . | P values . |
|---|---|---|---|
| Maternal characteristics | |||
| Maternal diagnosis | 0.03 | ||
| Asymptomatic | 6 (16) | 4 (58) | |
| SLE | 24 (63) | 1 (14) | |
| SS | 4 (10) | 1 (14) | |
| SLE/SS | 1 (3) | 0 (0) | |
| UCTD | 2 (5) | 0 (0) | |
| APS | 0 (0) | 1 (14) | |
| Dysautonomia | 1 (3) | 0 (0) | |
| Positive anti-La antibody | 12 (32) | 4 (57) | 0.24 |
| Maternal intake of fluorinated steroids | 0 (0) | 7 (100) | <0.01 |
| Maternal intake of IVIG | 1 (3) | 4 (58) | <0.01 |
| Maternal intake of non-fluorinated steroids | 7 (18) | 0 (0) | 0.57 |
| Maternal intake of antimalarials | 14 (37) | 1 (14) | 0.40 |
| Prenatal complicationsa | 8 (21) | 3 (43) | 0.34 |
| Vaginal delivery | 24 (63) | 1 (14) | 0.03 |
| Infant characteristics | |||
| Sex F:M | 19:19 (50:50) | 5:2 (71:29) | 0.42 |
| Gestational age, weeks | 38.0 (37.0–39.0) | 35.5 (34.5–38.0) | 0.03 |
| Birth weight, kg | 3.0 (2.6–3.5) | 2.3 (1.8–2.5) | 0.02 |
| Neonatal complicationsb | 9 (24) | 2 (29) | 0.99 |
| Infant received non-fluorinated steroids | 0 (0) | 7 (100) | <0.01 |
| Infant received IVIG | 0 (0) | 5 (71) | <0.01 |
| Age at first hs-cTnT measurement, days | 55 (43–78) | 5 (2–26) | <0.01 |
| First hs-cTnT measurement, ng/l | 37 (24–61) | 67 (49–310)c | 0.03 |
| . | No cardiac NLE (N = 38) . | Cardiac NLE (N = 7) . | P values . |
|---|---|---|---|
| Maternal characteristics | |||
| Maternal diagnosis | 0.03 | ||
| Asymptomatic | 6 (16) | 4 (58) | |
| SLE | 24 (63) | 1 (14) | |
| SS | 4 (10) | 1 (14) | |
| SLE/SS | 1 (3) | 0 (0) | |
| UCTD | 2 (5) | 0 (0) | |
| APS | 0 (0) | 1 (14) | |
| Dysautonomia | 1 (3) | 0 (0) | |
| Positive anti-La antibody | 12 (32) | 4 (57) | 0.24 |
| Maternal intake of fluorinated steroids | 0 (0) | 7 (100) | <0.01 |
| Maternal intake of IVIG | 1 (3) | 4 (58) | <0.01 |
| Maternal intake of non-fluorinated steroids | 7 (18) | 0 (0) | 0.57 |
| Maternal intake of antimalarials | 14 (37) | 1 (14) | 0.40 |
| Prenatal complicationsa | 8 (21) | 3 (43) | 0.34 |
| Vaginal delivery | 24 (63) | 1 (14) | 0.03 |
| Infant characteristics | |||
| Sex F:M | 19:19 (50:50) | 5:2 (71:29) | 0.42 |
| Gestational age, weeks | 38.0 (37.0–39.0) | 35.5 (34.5–38.0) | 0.03 |
| Birth weight, kg | 3.0 (2.6–3.5) | 2.3 (1.8–2.5) | 0.02 |
| Neonatal complicationsb | 9 (24) | 2 (29) | 0.99 |
| Infant received non-fluorinated steroids | 0 (0) | 7 (100) | <0.01 |
| Infant received IVIG | 0 (0) | 5 (71) | <0.01 |
| Age at first hs-cTnT measurement, days | 55 (43–78) | 5 (2–26) | <0.01 |
| First hs-cTnT measurement, ng/l | 37 (24–61) | 67 (49–310)c | 0.03 |
Data shown as median (IQR) or N (%), unless otherwise specified.
Prenatal complications in mothers of infants without cardiac NLE: premature rupture of membranes (N = 1), deep venous thrombosis (N = 1), pemphigoïd gestationis (N = 1), hypertension (N = 2), oligohydramnios (N = 1), maternal fever during labour (N = 1) and fetal growth delay (N = 1); prenatal complications in mothers of infants with cardiac NLE: paronychia and upper respiratory tract infection (N = 1), oligohydramnios (N = 1) and gestational diabetes (N = 1).
Neonatal complications in infants without cardiac NLE: NLE-related thrombocytopenia (N = 1), hyperbilirubinemia requiring phototherapy (N = 2), umbilical cord knot (N = 1), nuchal cord, vacuum-assisted delivery and CPAP requirement for 24 h (N = 1), hypoglycaemia (N = 1), transient heart-rate irregularity (N = 1), gastrointestinal infection (N = 1) and group B Streptococcal sepsis and hyperbilirubinemia requiring phototherapy (N = 1); neonatal complications in infants with cardiac NLE: intubation and haemodynamic instability requiring vasopressors (N = 2).
Median (IQR) of first hs-cTnT measurement, ng/l in cardiac NLE infants (N = 5) without a pacemaker inserted: 65 (37–78); P = 0.20 vs infants without cardiac NLE. CPAP: continuous positive airway pressure; F: female; hs-cTnT: high-sensitivity cardiac troponin T; IQR: interquartile range; M: male; NLE: neonatal lupus erythematosus.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
